NCT05239741: An ongoing trial by Merck Sharp & Dohme LLC
This trial is ongoing. It must report results 3 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05239741 |
|---|---|
| Title | A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 2, 2022 |
| Completion date | Sept. 19, 2028 |
| Required reporting date | Sept. 19, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |